FarmaMondo has recently hosted two days of medical workshops in Saint Petersburg and Moscow on November 9th and 10th 2017, as part of its support for the exclusive managed access program of Dinutuximab beta EUSA to fulfill the unmet medical needs of patients with high-risk neuroblastoma, in all the CIS countries and Georgia.
The successful medical workshop sessions were led by the well-known guest speaker, Dr. Dermot Murphy, a pediatric oncologist at the Royal Hospital for Children in Glasgow, Scotland, a member and past co-chair of the Neuroblastoma Special Interest Group in the Children‘s Cancer and Leukemia Group (CCLG) and a member of the SIOPEN group.
Following FarmaMondo‘s invitation, 45 leading local Key Opinion Leaders (KOLs) in neuroblastoma participated in the High risk neuroblastoma Patients‘ medical workshops.
The purpose of the medical workshops was to receive guidance from Dr. Murphy, and to gain from his practical experience with neuroblastoma treatment, while providing an opportunity for an exchange of views between Dr. Murphy and the group of the local KOLs, regarding all the major aspects of high risk Neuroblastoma management.
About Neuroblastoma and Dinutuximab beta EUSA
Neuroblastoma is an orphan oncology condition with significant unmet medical need. It accounts for up to 10% of childhood tumors. Dinutuximab beta EUSA was used extensively across Europe under a managed access scheme before the EMA marketing authorization and is included in a number of treatment protocols for high-risk neuroblastoma.
Dinutuximab beta EUSA, an anti-GD2 monoclonal antibody, is indicated for children aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed or refractory neuroblastoma, with or without residual disease
About FarmaMondo
FarmaMondo, established in 1915, is a Swiss-based pharmaceutical service provider focusing on facilitating patients’ access to their unmet medical needs via regulated access mechanisms known as Early Access, Named Patient and Compassionate Use.
FarmaMondo collaborates with innovators who seek to establish pre-commercial availability of their novel therapies to highly targeted groups of patients in territories where medical needs are unmet, in an ethical and compliant manner.
FarmaMondo is the Unlicensed Medicine access partner for thousands of Healthcare Professionals and Institutions globally who seek an ethical and compliant service provider to address their needs for therapies which are commercially unavailable in their home country.
FarmaMondo presence in Russia & CIS has recently been upgraded by establishing a local representative office in Moscow.
Follow Us on FM Social Media Channels for more info!
